Press releases

Month Year

Email alerts

Jan 10, 2013

New Clinical Trial First To Evaluate Effectiveness of CRT-P in Symptomatic Heart Failure Patients with Mild-to-Moderate Structural Heart Disease

Medtronic-Sponsored Study Aims to Support Worldwide Indication Expansion for CRT-P in a Significantly Underserved Heart Failure Patient Population

MINNEAPOLIS - Jan. 10, 2013 - Medtronic, Inc. (NYSE: MDT) today announced the first patient enrollment in MIRACLE EF, a global clinical trial that will evaluate the effectiveness of cardiac...
Jan 7, 2013

Medtronic Updates Fiscal 2013 EPS Guidance

MINNEAPOLIS - January 7, 2013 - In a presentation to investors, Medtronic, Inc. (NYSE:MDT) today updated diluted earnings per share (EPS) guidance for fiscal year 2013. The Company tightened its...
Dec 17, 2012

One-Year Results from the Symplicity HTN-2 Randomized Controlled Trial Published in Circulation

Published data demonstrate the Symplicity(TM) renal denervation system provides blood pressure reduction in patients with treatment-resistant hypertension sustained to 12 months

MINNEAPOLIS - December 17, 2012 - Medtronic, Inc. (NYSE: MDT) today announced that one-year results from Symplicity HTN-2, the first randomized clinical trial investigating renal denervation, were...
Dec 12, 2012

Medtronic CFO Gary Ellis to Speak at Oppenheimer Healthcare Conference

MINNEAPOLIS - Dec 4, 2012 - Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the Oppenheimer 23rd Annual Healthcare Conference on...
Dec 10, 2012

Medtronic CEO Omar Ishrak to Speak at JP Morgan Healthcare Conference

MINNEAPOLIS - Dec 10, 2012 - Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the JP Morgan 31st Annual Healthcare Conference on...

Show per page

Su	Mo	Tu	We	Th	Fr	Sa

Su	Mo	Tu	We	Th	Fr	Sa